BR9710156A - Composto composições para tratar uma doença cardiovascular assinalada por hipertens o ou isquemia de miocárdio para melhorar lesão isquêmica ou reduzir tamanho de infarto do miocárdio e para reduzir ou níveis de lipídeo os níveis de trigricerídeo ou os níveis de colesterol em um mamífero processos para tratar um paciente sofrendo de hipertensão para tratar um paciente sofrendo de isquemia do miocárdio e para tratar um paciente sofrendo de hiperlipidemia ou de hipercolesterolemia - Google Patents

Composto composições para tratar uma doença cardiovascular assinalada por hipertens o ou isquemia de miocárdio para melhorar lesão isquêmica ou reduzir tamanho de infarto do miocárdio e para reduzir ou níveis de lipídeo os níveis de trigricerídeo ou os níveis de colesterol em um mamífero processos para tratar um paciente sofrendo de hipertensão para tratar um paciente sofrendo de isquemia do miocárdio e para tratar um paciente sofrendo de hiperlipidemia ou de hipercolesterolemia

Info

Publication number
BR9710156A
BR9710156A BR9710156A BR9710156A BR9710156A BR 9710156 A BR9710156 A BR 9710156A BR 9710156 A BR9710156 A BR 9710156A BR 9710156 A BR9710156 A BR 9710156A BR 9710156 A BR9710156 A BR 9710156A
Authority
BR
Brazil
Prior art keywords
treat
patient suffering
hypertension
reduce
levels
Prior art date
Application number
BR9710156A
Other languages
English (en)
Portuguese (pt)
Inventor
Michael R Myers
Martin P Maguire
Alfred P Spada
William R Ewing
Henry W Pauls
Yong-Mi Choi-Sledeski
Original Assignee
Rhone Poulenc Rorer Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Pharma filed Critical Rhone Poulenc Rorer Pharma
Publication of BR9710156A publication Critical patent/BR9710156A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR9710156A 1996-07-08 1997-07-01 Composto composições para tratar uma doença cardiovascular assinalada por hipertens o ou isquemia de miocárdio para melhorar lesão isquêmica ou reduzir tamanho de infarto do miocárdio e para reduzir ou níveis de lipídeo os níveis de trigricerídeo ou os níveis de colesterol em um mamífero processos para tratar um paciente sofrendo de hipertensão para tratar um paciente sofrendo de isquemia do miocárdio e para tratar um paciente sofrendo de hiperlipidemia ou de hipercolesterolemia BR9710156A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2136696P 1996-07-08 1996-07-08
PCT/US1997/011320 WO1998001426A1 (en) 1996-07-08 1997-07-01 Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties

Publications (1)

Publication Number Publication Date
BR9710156A true BR9710156A (pt) 1999-08-10

Family

ID=21803790

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9710156A BR9710156A (pt) 1996-07-08 1997-07-01 Composto composições para tratar uma doença cardiovascular assinalada por hipertens o ou isquemia de miocárdio para melhorar lesão isquêmica ou reduzir tamanho de infarto do miocárdio e para reduzir ou níveis de lipídeo os níveis de trigricerídeo ou os níveis de colesterol em um mamífero processos para tratar um paciente sofrendo de hipertensão para tratar um paciente sofrendo de isquemia do miocárdio e para tratar um paciente sofrendo de hiperlipidemia ou de hipercolesterolemia

Country Status (22)

Country Link
EP (1) EP0912520B1 (enExample)
JP (1) JP4202421B2 (enExample)
KR (1) KR20000023635A (enExample)
CN (1) CN1228770A (enExample)
AP (1) AP903A (enExample)
AT (1) ATE239725T1 (enExample)
AU (1) AU746590B2 (enExample)
BG (1) BG103135A (enExample)
BR (1) BR9710156A (enExample)
CA (1) CA2259538C (enExample)
CZ (1) CZ291785B6 (enExample)
DE (1) DE69721776T2 (enExample)
EA (1) EA001801B1 (enExample)
ES (1) ES2199365T3 (enExample)
HU (1) HUP9903815A3 (enExample)
IL (1) IL127890A0 (enExample)
NO (1) NO313671B1 (enExample)
OA (1) OA10953A (enExample)
PL (1) PL331036A1 (enExample)
SK (1) SK2299A3 (enExample)
UA (1) UA51716C2 (enExample)
WO (1) WO1998001426A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376472B1 (en) * 1996-07-08 2002-04-23 Aventis Pharmaceuticals, Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
GB9723590D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
GB9813554D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
AU750462B2 (en) 1998-06-23 2002-07-18 Glaxo Group Limited 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
JP3598332B2 (ja) * 1998-11-25 2004-12-08 株式会社第一ラジオアイソトープ研究所 Ｎ−アシルオキシ環状アルキル化合物を有効成分とする医薬品および試薬
JP2002534430A (ja) * 1998-12-31 2002-10-15 アベンティス・ファーマスーティカルズ・プロダクツ・インコーポレイテツド Ｎ６−置換デアザアデノシン誘導体類の製造法
GB0106867D0 (en) * 2001-03-20 2001-05-09 Glaxo Group Ltd Process
CA2446605A1 (en) * 2001-05-10 2002-11-21 Aventis Pharma Deutschland Gmbh Novel processes for the preparation of adenosine compounds and intermediates thereto
EP1258247A1 (en) * 2001-05-14 2002-11-20 Aventis Pharma Deutschland GmbH Adenosine analogues for the treatment of insulin resistance syndrome and diabetes
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
HUP0200849A2 (hu) * 2002-03-06 2004-08-30 Sanofi-Synthelabo N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
EP1375508A1 (en) * 2002-06-27 2004-01-02 Aventis Pharma Deutschland GmbH N6-substituted adenosine analogues and their use as pharmaceutical agents
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
FR2862969A1 (fr) * 2003-11-28 2005-06-03 Oreal Procede de preparation de derives paraphenylenediamine a groupement pyrrolidinyle, substitue par un radical azote, et composes intermediaires
EP1574508A1 (de) 2004-01-30 2005-09-14 Lonza AG Verfahren zur Herstellung von Acetalen und Ketalen von 3-Amino-5-(hydroxymethyl)-cyclopentan-1,2-diolen, sowie deren Derivaten und Salzen
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
JP2006022045A (ja) * 2004-07-08 2006-01-26 Kaneka Corp 光学活性１−ｔ−ブトキシカルボニル−３−アミノピロリジン塩の単離精製方法
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
US7671062B2 (en) 2006-07-28 2010-03-02 Bristol-Myers Squibb Company Modulators of chemokine receptor activity, crystalline forms and process
US7629351B2 (en) 2006-07-28 2009-12-08 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process
US7687508B2 (en) 2006-07-28 2010-03-30 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
DE102007002260A1 (de) 2007-01-16 2008-07-31 Sanofi-Aventis Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms
US8383812B2 (en) 2009-10-13 2013-02-26 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
KR102758609B1 (ko) * 2016-01-14 2025-01-22 주식회사 한독 A3 아데노신 수용체 길항 화합물, 그의 제조 방법 및 그의 의학적 용도
CN110627765B (zh) * 2019-10-14 2021-08-20 浙江乐普药业股份有限公司 一种替卡格雷关键中间体的制备方法
CN112047919B (zh) * 2020-09-16 2021-06-18 常州制药厂有限公司 一种替卡格雷中间体及其制备方法
KR102308854B1 (ko) * 2021-02-26 2021-10-05 퓨쳐메디신 주식회사 카보사이클릭 뉴클레오사이드 유도체를 포함하는 코로나바이러스감염증-19 예방 및 치료용 약학적 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
WO1992005177A1 (en) * 1990-09-25 1992-04-02 Rhone-Poulenc Rorer International (Holdings) Inc. Compounds having antihypertensive and anti-ischemic properties
WO1995018817A1 (fr) * 1994-01-07 1995-07-13 Laboratoires Upsa Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant
US5554746A (en) * 1994-05-16 1996-09-10 Isis Pharmaceuticals, Inc. Lactam nucleic acids

Also Published As

Publication number Publication date
AU3645497A (en) 1998-02-02
BG103135A (bg) 1999-11-30
DE69721776T2 (de) 2004-03-25
EA001801B1 (ru) 2001-08-27
ES2199365T3 (es) 2004-02-16
EP0912520A4 (en) 1999-10-06
JP2000514801A (ja) 2000-11-07
CZ2499A3 (cs) 1999-05-12
DE69721776D1 (de) 2003-06-12
CA2259538A1 (en) 1998-01-15
CN1228770A (zh) 1999-09-15
SK2299A3 (en) 2000-10-09
EP0912520A1 (en) 1999-05-06
AU746590B2 (en) 2002-05-02
EA199900092A1 (ru) 1999-08-26
HUP9903815A3 (en) 2002-04-29
AP9801426A0 (en) 1998-12-31
IL127890A0 (en) 1999-10-28
CZ291785B6 (cs) 2003-05-14
NO990063L (no) 1999-03-08
PL331036A1 (en) 1999-06-21
JP4202421B2 (ja) 2008-12-24
UA51716C2 (uk) 2002-12-16
ATE239725T1 (de) 2003-05-15
NO990063D0 (no) 1999-01-07
HUP9903815A1 (hu) 2001-04-28
NO313671B1 (no) 2002-11-11
AP903A (en) 2000-11-24
KR20000023635A (ko) 2000-04-25
OA10953A (en) 2001-10-26
EP0912520B1 (en) 2003-05-07
CA2259538C (en) 2006-12-19
WO1998001426A1 (en) 1998-01-15

Similar Documents

Publication Publication Date Title
BR9710156A (pt) Composto composições para tratar uma doença cardiovascular assinalada por hipertens o ou isquemia de miocárdio para melhorar lesão isquêmica ou reduzir tamanho de infarto do miocárdio e para reduzir ou níveis de lipídeo os níveis de trigricerídeo ou os níveis de colesterol em um mamífero processos para tratar um paciente sofrendo de hipertensão para tratar um paciente sofrendo de isquemia do miocárdio e para tratar um paciente sofrendo de hiperlipidemia ou de hipercolesterolemia
BR9507327A (pt) Composto composições para tratar uma donça cardiovascular marcada por hipertensão ou hipertensão ou isquemia do miocárdio melhorar os danos isquémicos ou reduzir o tamanho do infarto do miocárdio e reduzir niveis de lipideos triglicerideos ou de colesterol em um mamifero e processos para tratar um paciente que sofre de hipertensão de isquemia do miocárdio e de hiperlipidemia ou hipercolesterolina para melhorar em um paciente danos isquémicos ou o tamanho do infarto do miocádio e para preparar um derivado substancialmente opticamente puro de 2 substituido-2-amido-1-(heteroar-2-3-il) etano
EP1045636A4 (en) PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD FOR DAMAGED MYOCARD TISSUE
CO4970694A1 (es) Amlodipino y atorvastatina utiles en el tratamiento de angina de pecho, ateroesclerosis, hipertension e hiperlipidemia
PT1023891E (pt) Composicao anidra de descoloracao das fibras queratinicas compreendendo a associacao de polimeros anfifilicos anionicos e/ou nao ionicos compreendendo pelo menos uma cadeia gorda e de polimeros substantivos cationicos ou anfotericos
MA24391A1 (fr) Progesterone pour traiter ou reduire l'ischemie
FR16C0008I2 (fr) Utilisation combinee de valsartane et bloqueurs du canal de calcium a but therapeutique
TNSN98155A1 (fr) Associations de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs, et procede pour leur preparation
EE04390B1 (et) Paikne preparaat dermatoloogiliste seisundite raviks
BR9508586A (pt) Compostos processo de preparação dos mesmos uso dos mesmos processo de tratamento de uma condição clínica em um mamífero e composição farmacêutica
TNSN98158A1 (fr) Associations pharmaceutiques d'amlodipine et d'une statine, et procede pour leur preparation
CY2010002I2 (el) Στepεη φαρμακευτικη συνθεση πepιεχοντας παραγωγα βενζοφουρανιου
FR2752734B1 (fr) Utilisation de retinoides pour la preparation d'un medicament destine a traiter les affections liees a une surexpression de vegf
BR9916045B1 (pt) processo para a preparação de uma composição de lavagem.
MA26739A1 (fr) Sel mutuel d'amlodipine et d'atorvastatine, procede pour sa preparation et compositions pharmaceutiques les contenant
BR9802084A (pt) Processo para operar uma máquina hidráulica
FI953915A7 (fi) Dupuytrenin taudin lievittämiseen
EP0946178A4 (en) COMBINATION THERAPY TO REDUCE THE RISKS OF HEART CIRCULAR DISEASES
BG106149A (en) Mutual prodrugs of amlodipine and atorvastatin
BR9711225A (pt) Composi-{es de propentofilina transd-rmica para o tratamento do mal de alzheimer
FR2778849B1 (fr) Utilisation d'arabinoxylanes pour la preparation d'une composition destinee a prevenir ou traiter des desordres ou des pathologies lies a des dysfonctionnements metaboliques
BR0313209A (pt) proteìnas que interagem com mk2
AR020327A1 (es) Uso de una cantidad terapeuticamente efectiva de (-)norcisaprida, o una sal farmacologicamente aceptable de la misma, sustancialmente libre de su (+)estereoisomero, para la preparacion de medicamentos.
DK0710315T3 (da) Forskallingsplade med drager med omtrentligt U-formet tværsnit
DZ2654A1 (fr) Utilisations des kétolides pour la préparation de compositions pharmaceutiques destinées à prévenir les complications thrombotiques artérielles liées à l'arthérosclérose.

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B25D Requested change of name of applicant approved
B25G Requested change of headquarter approved
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1891 DE 03/04/2007.